Bruno Fang

828 total citations
33 papers, 458 citations indexed

About

Bruno Fang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Bruno Fang has authored 33 papers receiving a total of 458 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 7 papers in Cancer Research. Recurrent topics in Bruno Fang's work include Cancer Immunotherapy and Biomarkers (13 papers), Lung Cancer Treatments and Mutations (12 papers) and Cancer Genomics and Diagnostics (6 papers). Bruno Fang is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Lung Cancer Treatments and Mutations (12 papers) and Cancer Genomics and Diagnostics (6 papers). Bruno Fang collaborates with scholars based in United States, Spain and Italy. Bruno Fang's co-authors include Edison T. Liu, Olga Aprelikova, Amy J. Pace, Beverly H. Koller, Roy A. Jensen, Shane E. Cotter, Eric G. Meissner, Mika Bessho, Ryan D. Gentzler and Connie Wong and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Bruno Fang

27 papers receiving 445 citations

Peers

Countries citing papers authored by Bruno Fang

Since Specialization

Citations

This map shows the geographic impact of Bruno Fang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruno Fang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruno Fang more than expected).

Fields of papers citing papers by Bruno Fang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruno Fang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruno Fang. The network helps show where Bruno Fang may publish in the future.

Co-authorship network of co-authors of Bruno Fang

This figure shows the co-authorship network connecting the top 25 collaborators of Bruno Fang. A scholar is included among the top collaborators of Bruno Fang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruno Fang. Bruno Fang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study 2024 ·JTO Clinical and Research Reports ·Joel W. Neal, Armando Santoro, María González‐Cao, Farah Louise Lim, Bruno Fang, Ryan D. Gentzler, Jerome H. Goldschmidt, (unknown), Claudia Proto, Shiven B. Patel, Sonam Puri, Stephen V. Liu, Erminia Massarelli, (unknown), (unknown), Christian Scheffold, (unknown), Enriqueta Felip	2
2	Clinical Value of Timely Targeted Therapy for Patients With Advanced Non–Small Cell Lung Cancer With Actionable Driver Oncogenes 2024 ·The Oncologist ·Thomas Stricker, (unknown), Esprit Ma, Elaine Yu, Rongrong Wang, (unknown), Richard Price, Tania Szado, (unknown), Sarika Ogale, (unknown), Edward Arrowsmith, Dennis Slater, Daniel A. Vaena, Harry Staszewski, Bruno Fang, Lasika Seneviratne, Davey B. Daniel	4
3	Safety and Tolerability of Magrolimab Combination Therapy in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (RM-HNSCC) 2024 ·International Journal of Radiation OncologyBiologyPhysics ·A. Dimitrios Colevas, (unknown), (unknown), (unknown), (unknown), Bruno Fang, Diogo Alpuim Costa, José Dinis, (unknown), (unknown), (unknown), (unknown), Michael F. Howland, (unknown), Douglas Adkins	0
4	3MO Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutant advanced NSCLC after progression on osimertinib: A post-progression analysis of MARIPOSA-2 2024 ·ESMO Open ·Ryan D. Gentzler, Alexander I. Spira, Barbara Melosky, Scott Owen, Timothy F. Burns, Erminia Massarelli, Misako Nagasaka, Bruno Fang, Rachel E. Sanborn, (unknown), (unknown), Federico Cappuzzo, Kun Xia, (unknown), Shalin Shah, B. Diorio, (unknown), (unknown), Joshua Bauml, Karen L. Reckamp	2
5	390P Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Update of dose escalation results from a phase I/II trial 2023 ·Annals of Oncology ·Erika Hamilton, Hyo S. Han, Anne F. Schott, Antoinette R. Tan, Rita Nanda, Dejan Juric, (unknown), Pamela N. Münster, Bruno Fang, (unknown), (unknown), Richard Gedrich, Eric Zhi, (unknown), Weiwei Tan, (unknown), Jessica M. Perkins, Sibyl Anderson, Sara A. Hurvitz	12
6	Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences 2023 ·Targeted Oncology ·Jacqueline C. Barrientos, Ayed O. Ayed, (unknown), (unknown), Bruno Fang, Ryan Hall, Stanley M. Marks, (unknown), Joanna Rhodes, Kellie Ryan, Sharon Winters, Percy Luk Yeung, Jing‐Zhou Hou	1
7	698 Safety and tolerability of magrolimab in combination with taxanes in patients with solid tumors 2023 ·SHILAP Revista de lepidopterología ·(unknown), Joanne Chiu, Ulka N. Vaishampayan, Rohit Joshi, Muhammad Furqan, (unknown), Bruno Fang, William Lawler, (unknown), Wen Xu, (unknown), (unknown), Ann Chen, (unknown), (unknown), Sylvia Adams	0
8	Clinical value of timely targeted therapy (TT) for patients with advanced non-small cell lung cancer (aNSCLC) with actionable driver oncogenes (ADO). 2023 ·Journal of Clinical Oncology ·Thomas Stricker, (unknown), Elaine Yu, Esprit Ma, (unknown), Rongrong Wang, (unknown), Sarika Ogale, Tania Szado, Richard Price, (unknown), Dennis Slater, Daniel A. Vaena, Harry Staszewski, Bruno Fang, Lasika Seneviratne, Edward Arrowsmith, Davey B. Daniel	1
9	675 Safety and tolerability of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (RM-HNSCC) 2023 ·SHILAP Revista de lepidopterología ·A. Dimitrios Colevas, (unknown), Venessa Chin, (unknown), John Park, Bruno Fang, Diogo Alpuim Costa, José Dinis, (unknown), Lanjia Lin, Yiran Zhang, (unknown), Michael F. Howland, Kelly K. Curtis, Douglas Adkins	0
10	Overall survival in patients with metastatic or locally advanced pancreatic cancer following chemoradiation with novel combination of aldoxorubicin, N-803 IL-15 superagonist, and PDL1- NK cell therapy. 2023 ·Journal of Clinical Oncology ·Tara Elisabeth Seery, Chaitali Nangia, (unknown), Bruno Fang, (unknown), Leonard S. Sender, Sandeep K. Reddy, Patrick Soon‐Shiong	4
11	Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021) 2022 ·The Lancet Oncology ·Neeraj Agarwal, Bradley A. McGregor, Benjamin L. Maughan, Tanya B. Dorff, William Kevin Kelly, Bruno Fang, Rana R. McKay, Parminder Singh, Lance C. Pagliaro, Robert Dreicer, Sandy Srinivas, Yohann Loriot, Ulka N. Vaishampayan, Sanjay Goel, (unknown), Ashok Panneerselvam, (unknown), Toni K. Choueiri, Sumanta K. Pal	43
12	Abstract OT1-14-01: Zanidatamab in combination with ALX148 in advanced human epidermal growth factor receptor 2 (HER2)-expressing cancers, including breast cancer: A phase 1b/2, multicenter, open-label, dose-finding and cohort-expansion study (ZWI-ZW25-204) 2022 ·Cancer Research ·Sara A. Hurvitz, Jorge Chaves, Adam Brufsky, Alberto J. Montero, Bruno Fang, Kay T. Yeung, Manish R. Patel, Ritesh Parajuli, (unknown), Elaina M. Gartner, Abraham Fong, Sophia Randolph, Funda Meric‐Bernstam	3
13	A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib + rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC). 2022 ·Journal of Clinical Oncology ·David Pook, Daniel M. Geynisman, Joan Carles, Filippo de Braud, Anthony M. Joshua, José Luis Perez‐Gracia, (unknown), Sang Joon Shin, Bruno Fang, Minal Barve, Marco Maruzzo, Sergio Bracarda, Miso Kim, Yannick Kerloëguen, Jorge D. Gallo, Sophia L. Maund, Adam Harris, (unknown), Dhruvitkumar S. Sutaria, Howard Gurney	5
14	Phase 2/3, randomized, open-label study of an individualized neoantigen vaccine (self-amplifying mRNA and adenoviral vectors) plus immune checkpoint blockade as maintenance for patients with newly diagnosed metastatic colorectal cancer (GRANITE). 2022 ·Journal of Clinical Oncology ·J. Randolph Hecht, Ardaman Shergill, (unknown), Bruno Fang, (unknown), Heinz‐Josef Lenz, Lyudmyla Berim, Paul E. Oberstein, Rachael A. Safyan, (unknown), Heloisa P. Soares, David R. Spigel, Alexander I. Spira, Andrew R. Ferguson, Brian A. Chauder, Alexander Starodub	12
15	Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: Results from cohort 7 of the COSMIC-021 study. 2020 ·Journal of Clinical Oncology ·Joel W. Neal, Farah Louise Lim, Enriqueta Felip, Ryan D. Gentzler, Shiven B. Patel, Joaquina Baranda, Bruno Fang, (unknown), Matteo Simonelli, Scott Werneke, (unknown), Santiago Ponce Aix	28
16	Ibrutinib Dose Reductions and Discontinuations Patterns Among Patients with Chronic Lymphocytic Leukemia from a Large Community Medical Oncology Practice 2020 ·Blood ·(unknown), Bruno Fang, Percy Luk Yeung, (unknown), (unknown)	1
17	Dose Reductions and Discontinuations with Chronic Lymphocytic Leukemia (CLL) Patients Receiving Ibrutinib in Community and Academic Settings 2020 ·Blood ·Jing‐Zhou Hou, Kellie Ryan, (unknown), Bruno Fang, Stanley M. Marks, Ray D. Page, (unknown), Keith Szymanski, Sharon Winters, (unknown)	1
18	BRCA1 Is a Selective Co-activator of 14-3-3ς Gene Transcription in Mouse Embryonic Stem Cells 2001 ·Journal of Biological Chemistry ·Olga Aprelikova, Amy J. Pace, Bruno Fang, Beverly H. Koller, Edison T. Liu	82
19	Report of a factor VIII inhibitor in a patient with autoimmune lymphoproliferative syndrome 2000 ·American Journal of Hematology ·Bruno Fang, (unknown), Stephen E. Straus, Lawrence D. Frenkel, Janet K. Dale, Margaret E. Rick	13
20	BRCA1-associated growth arrest is RB-dependent 1999 ·Proceedings of the National Academy of Sciences ·Olga Aprelikova, Bruno Fang, Eric G. Meissner, Shane E. Cotter, (unknown), (unknown), Mika Bessho, Roy A. Jensen, Edison T. Liu	129

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact